Market Cap 47.52B
Revenue (ttm) 6.07B
Net Income (ttm) 1.07B
EPS (ttm) N/A
PE Ratio 31.96
Forward PE 28.58
Profit Margin 17.69%
Debt to Equity Ratio 0.06
Volume 5,617,600
Avg Vol 4,583,644
Day's Range N/A - N/A
Shares Out 580.80M
Stochastic %K 22%
Beta 0.93
Analysts Strong Sell
Price Target $96.07

Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provide...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 250 2500
Address:
One Edwards Way, Irvine, United States
TheWolfOfSanFran
TheWolfOfSanFran Mar. 11 at 3:47 AM
$AORT strong EBITDA growth and niche structural heart portfolio…. M&A 8x premium multiple ~$78 a share price target? Call me crazy but could be possible $MDT $BSC $EW $JNJ
1 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 2:57 PM
5 medical instrument stocks flashing serious short-term upside 👀 $ISRG $GMED $EW $ALC $IRMD are getting attention as AI tools, acquisitions, and new product pipelines fuel growth expectations — a combo that often sparks momentum in this space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-teaser-36722&ADID=SYND_STOCKTWITS_TWEET_2_2881459_TEASER_36722
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 1:57 PM
Five medical instrument stocks with significant short-term potential! 🚀 🤖 $ISRG leads the charge with AI-driven innovations, boasting a Zacks Rank #1 and a short-term price target indicating a 26% increase from its last close, with an upside of up to 52%. 💼 $GMED strengthens its position with strategic mergers, a debt-free balance sheet, and a promising pipeline, marked by a Zacks Rank #1 and a short-term target of a 24.7% gain, with an upside of up to 40.1%. 💔 $EW is advancing its Structural Heart business, supported by a Zacks Rank #2 and a short-term price target increase of 14%, with a maximum upside of 30.5%. 👓 $ALC capitalizes on its Vision Care innovations, with a Zacks Rank #2 and a short-term target increase of 13.9%, with an upside of up to 36.8%. 🩺 $IRMD expands with MRI-compatible products, holding a Zacks Rank #2 and a forecasted 19.9% rise, with an upside of 20%. Explore the full growth story here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-body-36721&ADID=SYND_STOCKTWITS_TWEET_2_2881459_BODY_36721
0 · Reply
GettnFibbywIT
GettnFibbywIT Mar. 5 at 4:25 PM
$EW $XLV $IHI Kryptonite is to Superman as the $87 ish area has been to Edwards...
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 1 at 2:42 AM
$MASI trading at $175 with volume slightly above average, while $EW sitting at $86 with volume significantly above average. MASI showing more strength with a higher price level compared to EW. MedicalTech sector heating up, will one outshine the other in the long run?
0 · Reply
PaulLaurent
PaulLaurent Feb. 26 at 7:28 AM
🔥 Breakout Scanner (4) — February 26, 2026 NFA. Risk: use 1–2% capital per trade. $CNP – Trigger 43.19 | SL 34.55 | Scores: F50 V41 G76 Q38 VAL56 (stable). News (24h): no fresh company-specific headline spotted. $EW – Trigger 83.50 | SL 66.80 | Scores: F49 V38 G40 Q66 VAL52 (stable). News (24h): filed annual Form 10-K. $PM – Trigger 190.00 | SL 152.00 | Scores: F59 V52 G55 Q69 VAL41 (stable). News (24h): no fresh company-specific headline spotted. $VST – Trigger 177.00 | SL 141.60 | Scores: F44 V50 G23 Q54 VAL56 (stable). News (24h): no fresh company-specific headline spotted.
0 · Reply
fjsteven
fjsteven Feb. 17 at 4:54 PM
$EW this is moving today cause MDT released their six and seven year low risk data and it sucked.
1 · Reply
GettnFibbywIT
GettnFibbywIT Feb. 17 at 3:23 PM
$EW $XLV $IHI Edwards (EW) is rebounding off the lower boundary of its long‑term rising weekly channel. A weekly close back above the round‑number $80 level and the 7/21/25 weekly close — paired with RSI reclaiming the 50 line — would signal a constructive momentum shift. For traders who use structured credit spreads, a bull put spread placed a few months out with the short strike set below the 10/13/25 weekly low aligns with the underlying support structure and offers a defined‑risk way to potentially express an early bullish reversal thesis. This is not a recommendation to buy or sell, but rather a potential near‑term strategy idea that fits the current technical construct:
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 13 at 1:26 PM
$EW Share Price: $76.43 Contract Selected: Jun 18, 2026 $80 Calls Buy Zone: $3.47 – $4.29 Target Zone: $6.07 – $7.42 Potential Upside: 65% ROI Time to Expiration: 124 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
erevnon
erevnon Feb. 11 at 6:40 PM
Goldman Sachs maintains Edwards Lifesciences $EW at Buy and lowers the price target from $108 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Latest News on EW
Edwards Lifesciences Reports Fourth Quarter Results

Feb 10, 2026, 4:15 PM EST - 4 weeks ago

Edwards Lifesciences Reports Fourth Quarter Results


Edwards Comments on JenaValve Acquisition

Jan 9, 2026, 6:48 PM EST - 2 months ago

Edwards Comments on JenaValve Acquisition


Top small-cap plays for 2026

Nov 25, 2025, 1:24 PM EST - 3 months ago

Top small-cap plays for 2026

A COHR DG TXT VLO


Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

Oct 30, 2025, 4:38 PM EDT - 4 months ago

Edwards Lifesciences CFO Scott Ullem to step down by mid-2026


Edwards Lifesciences Announces CFO Transition Plan

Oct 30, 2025, 4:15 PM EDT - 4 months ago

Edwards Lifesciences Announces CFO Transition Plan


Edwards Lifesciences Reports Third Quarter Results

Oct 30, 2025, 4:13 PM EDT - 4 months ago

Edwards Lifesciences Reports Third Quarter Results


Edwards Lifesciences: Inflection Incoming, But When?

Oct 14, 2025, 2:36 PM EDT - 5 months ago

Edwards Lifesciences: Inflection Incoming, But When?


TheWolfOfSanFran
TheWolfOfSanFran Mar. 11 at 3:47 AM
$AORT strong EBITDA growth and niche structural heart portfolio…. M&A 8x premium multiple ~$78 a share price target? Call me crazy but could be possible $MDT $BSC $EW $JNJ
1 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 2:57 PM
5 medical instrument stocks flashing serious short-term upside 👀 $ISRG $GMED $EW $ALC $IRMD are getting attention as AI tools, acquisitions, and new product pipelines fuel growth expectations — a combo that often sparks momentum in this space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-teaser-36722&ADID=SYND_STOCKTWITS_TWEET_2_2881459_TEASER_36722
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 1:57 PM
Five medical instrument stocks with significant short-term potential! 🚀 🤖 $ISRG leads the charge with AI-driven innovations, boasting a Zacks Rank #1 and a short-term price target indicating a 26% increase from its last close, with an upside of up to 52%. 💼 $GMED strengthens its position with strategic mergers, a debt-free balance sheet, and a promising pipeline, marked by a Zacks Rank #1 and a short-term target of a 24.7% gain, with an upside of up to 40.1%. 💔 $EW is advancing its Structural Heart business, supported by a Zacks Rank #2 and a short-term price target increase of 14%, with a maximum upside of 30.5%. 👓 $ALC capitalizes on its Vision Care innovations, with a Zacks Rank #2 and a short-term target increase of 13.9%, with an upside of up to 36.8%. 🩺 $IRMD expands with MRI-compatible products, holding a Zacks Rank #2 and a forecasted 19.9% rise, with an upside of 20%. Explore the full growth story here 👉 https://www.zacks.com/stock/news/2881459/5-medical-instruments-stocks-to-buy-amid-huge-short-term-price-upside?cid=sm-stocktwits-2-2881459-body-36721&ADID=SYND_STOCKTWITS_TWEET_2_2881459_BODY_36721
0 · Reply
GettnFibbywIT
GettnFibbywIT Mar. 5 at 4:25 PM
$EW $XLV $IHI Kryptonite is to Superman as the $87 ish area has been to Edwards...
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 1 at 2:42 AM
$MASI trading at $175 with volume slightly above average, while $EW sitting at $86 with volume significantly above average. MASI showing more strength with a higher price level compared to EW. MedicalTech sector heating up, will one outshine the other in the long run?
0 · Reply
PaulLaurent
PaulLaurent Feb. 26 at 7:28 AM
🔥 Breakout Scanner (4) — February 26, 2026 NFA. Risk: use 1–2% capital per trade. $CNP – Trigger 43.19 | SL 34.55 | Scores: F50 V41 G76 Q38 VAL56 (stable). News (24h): no fresh company-specific headline spotted. $EW – Trigger 83.50 | SL 66.80 | Scores: F49 V38 G40 Q66 VAL52 (stable). News (24h): filed annual Form 10-K. $PM – Trigger 190.00 | SL 152.00 | Scores: F59 V52 G55 Q69 VAL41 (stable). News (24h): no fresh company-specific headline spotted. $VST – Trigger 177.00 | SL 141.60 | Scores: F44 V50 G23 Q54 VAL56 (stable). News (24h): no fresh company-specific headline spotted.
0 · Reply
fjsteven
fjsteven Feb. 17 at 4:54 PM
$EW this is moving today cause MDT released their six and seven year low risk data and it sucked.
1 · Reply
GettnFibbywIT
GettnFibbywIT Feb. 17 at 3:23 PM
$EW $XLV $IHI Edwards (EW) is rebounding off the lower boundary of its long‑term rising weekly channel. A weekly close back above the round‑number $80 level and the 7/21/25 weekly close — paired with RSI reclaiming the 50 line — would signal a constructive momentum shift. For traders who use structured credit spreads, a bull put spread placed a few months out with the short strike set below the 10/13/25 weekly low aligns with the underlying support structure and offers a defined‑risk way to potentially express an early bullish reversal thesis. This is not a recommendation to buy or sell, but rather a potential near‑term strategy idea that fits the current technical construct:
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 13 at 1:26 PM
$EW Share Price: $76.43 Contract Selected: Jun 18, 2026 $80 Calls Buy Zone: $3.47 – $4.29 Target Zone: $6.07 – $7.42 Potential Upside: 65% ROI Time to Expiration: 124 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
erevnon
erevnon Feb. 11 at 6:40 PM
Goldman Sachs maintains Edwards Lifesciences $EW at Buy and lowers the price target from $108 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
50bps
50bps Feb. 11 at 5:10 PM
$EW nice recovery
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 1:26 PM
$EW misses on Q4 EPS but tops revenue estimates — a mixed bag for investors 🤔 - Q4 EPS of 58 cents missed the Zacks Consensus Estimate by 5.89% 📉 - Q4 sales rose 13.3% YoY to $1.57B, beating estimates by 1.99% 🚀 - TAVR segment saw a 12% sales increase, reflecting strong demand Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2853826/ews-q4-earnings-miss-estimates-revenues-up-yy-stock-climbs?cid=sm-stocktwits-2-2853826-body-32973&ADID=SYND_STOCKTWITS_TWEET_2_2853826_BODY_32973
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 12:26 PM
$EW earnings miss… and the stock still climbs? 👀 Q4 earnings came in below estimates, but revenues were up year over year — and the market is clearly focusing on the growth, not the miss. When a stock rallies on an earnings miss, that tells you sentiment and forward expectations may be stronger than the headline suggests. Is this strength sustainable or just a short-term pop? Full breakdown here 👉 https://www.zacks.com/stock/news/2853826/ews-q4-earnings-miss-estimates-revenues-up-yy-stock-climbs?cid=sm-stocktwits-2-2853826-teaser-32968&ADID=SYND_STOCKTWITS_TWEET_2_2853826_TEASER_32968
0 · Reply
Thrasher5699
Thrasher5699 Feb. 10 at 11:36 PM
$EW Edwards Lifesciences (EW) is currently viewed as moderately undervalued by many Wall Street analysts, though traditional valuation multiples suggest a premium price. As of February 10, 2026, the stock trades around $77.05, while the consensus average price target of $96.77 implies a potential upside of approximately 24.8%.
1 · Reply
Thrasher5699
Thrasher5699 Feb. 10 at 10:05 PM
BUY $EW Great Earnings and 86% owned by institutions !
0 · Reply
Thrasher5699
Thrasher5699 Feb. 10 at 10:03 PM
BUY $EW
0 · Reply
Thrasher5699
Thrasher5699 Feb. 10 at 9:57 PM
$EW Going back over 120$ Great earnings!!!
0 · Reply
Thrasher5699
Thrasher5699 Feb. 10 at 9:51 PM
$EW 120$ here we come!
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 10 at 9:33 PM
$EW Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.16 down -75.38% YoY • Reported revenue of $1.57B up 13.26% YoY • Edwards Lifesciences has increased confidence in its FY 2026 constant currency sales growth guidance of 8-10% and adjusted EPS of $2.90-$3.05, and projects Q1 2026 sales between $1.55B.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 10 at 9:33 PM
$EW Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.16 down -75.38% YoY • Reported revenue of $1.57B up 13.26% YoY • Edwards Lifesciences increased confidence in FY 2026 constant currency sales growth of 8-10% and adjusted EPS of $2.90-$3.05. Edwards projects Q1 2026 sales between $1.55B and $1.63B.
0 · Reply
FannyPackin
FannyPackin Feb. 10 at 9:29 PM
$EW would like to see it reclaim 200 week.. will look to add this if it can break 90 and hold later this year..
1 · Reply
DonCorleone77
DonCorleone77 Feb. 10 at 8:16 PM
$EW Edwards Lifesciences options imply 5.3% move in share price post-earnings Pre-earnings options volume in Edwards Lifesciences is 4.3x normal with calls leading puts 5:4. Implied volatility suggests the market is anticipating a move near 5.3%, or $4.11, after results are released. Median move over the past eight quarters is 3.7%.
0 · Reply